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ABSTRACT
Nasopharyngeal carcinoma (NPC) has a high incidence and mortality rate in Southeast 
Asia included in Indonesia. Radioresistance is a major obstacle for a successful treatment 
of NPC. DNA repair in the cell cycle and angiogenesis factors affect the response of 
tumor cells to radiotherapy. Cyclin D1 that functions in the cell cycle process and vascular 
endothelial growth factor (VEGF) as an angiogenesis factor are considered to play a 
role in the occurrence of radioresistance. The objective of this study was to evaluate 
the association between cyclin D1 and VEGF expressions with radiotherapy response 
in undifferentiated NPC. This study used a retrospective case control analysis design. 
Secondary data from medical records of patients diagnosed as undifferentiated NPC who 
received a complete radiotherapy at the Department of Radiation Oncology, Dr. Hasan 
Sadikin General Hospital, Bandung. There were 44 samples divided into radiosensitive 
(22 samples) and radioresistant (22 samples) groups. Immunohistochemical examination 
of cyclin D1 and VEGF expressions was performed on paraffin blocks of patients’ 
nasopharyngeal biopsy. Data analysis used Chi-Square test with p ≤0.05. Cyclin D1 was 
expressed strongly in 86.4% of the radioresistant group and 59.1% in the radiosensitive 
group (p<0.05), VEGF was strongly expressed in 77.3% of the radioresistant group and 
54.5% in the radiosensitive group (p>0.05). In conclusion, there is significant association 
between cyclin D1 expression with radiotherapy response in undifferentiated NPC. 
However, there is no association between VEGF expression with radiotherapy response.
ABSTRAK
Karsinoma nasofaring merupakan keganasan dengan angka insidensi dan mortalitas 
tinggi di Asia Tenggara termasuk Indonesia. Radioresistensi menjadi hambatan utama 
dalam keberhasilan penanganan karsinoma nasofaring. Perbaikan DNA dalam siklus sel 
dan faktor angiogenesis mempengaruhi respons sel tumor terhadap radioterapi. Siklin D1 
yang berperan dalam siklus sel dan vascular endothelial growth factor (VEGF) sebagai 
faktor angiogenesis berperan dalam terjadinya radioresistensi. Penelitian ini bertujuan 
mengkaji hubungan antara ekspresi siklin D1 dan VEGF dengan respons radioterapi 
pada karsinoma nasofaring tidak berdiferensiasi. Penelitian ini menggunakan desain 
analisis retrospective case control.  Data sekunder yang digunakan berasal dari rekam 
medis pasien yang didiagnosis sebagai karsinoma nasofaring tidak berdiferensiasi yang 
mendapat radioterapi lengkap di Departemen Radiasi Onkologi, RSUP Dr Hasan Sadikin 
Bandung. Terdapat 44 sampel yang dibagi menjadi kelompok radiosensitif (22 sampel) 
dan radioresisten (22 sampel) berdasarkan respons radioterapi. Deteksi ekspresi siklin 
D1 dan VEGF dilakukan dengan pemeriksaan imunohistokimia pada blok paraffin sediaan 
biopsi nasofaring pasien. Analisis data menggunakan uji Chi-Square dengan nilai p ≤ 
0.05. Siklin D1 terekspresi kuat pada 86,4% kelompok radioresisten dan 59,1% pada 
kelompok radiosensitif (p<0.05), sedangkan VEGF terekspresi kuat pada 77,3% kelompok 
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INTRODUCTION
Nasopharyngeal carcinoma (NPC) 
is a malignancy originating from the 
nasopharyngeal epithelium.1 This 
malignancy has a high incidence rate in the 
East and Southeast Asia region. Based on 
GLOBOCAN 2012, there are 87,000 new 
cases emerging each year.2 In Indonesia, NPC 
is one of the most common malignancies, 
ranks the 4th in the most cancer incidence 
after breast cancer, cervical cancer, and lung 
cancer, makes the most frequent malignancy 
in the head and neck region. The incidence 
of NPC in Indonesia is 6.2 per 100,000 
populations per year with 13,000 new cases 
per year. Undifferentiated nasopharyngeal 
carcinoma is the most common subtype (90-
95%) found in endemic areas such as in Asia 
including in Indonesia.3
Radiotherapy is the standard choice of 
undifferentiated nasopharyngeal carcinoma 
treatment because of its sensitivity to 
radiotherapy and has difficult anatomical 
location for surgery.4 The radiotherapy has 
been a chosen treatment since many years 
and has been performed in various centers 
in the world. The outcomes of radiotherapy 
for early stage NPCs are actually quite 
good with the complete response is about 
80-100%. However, the outcomes of the 
radiotherapy for advanced stage NPCs drops 
significantly with 5-year survival rate less 
than 40% due to increased incidence of 
radioresistance.5 Chemoradiation is  one of 
the therapeutic modalities in the advanced 
stage of NPC, however in some cases 
chemotherapy becomes contraindication. 
Therefore, radiotherapy is the only modality 
in the advance stage of undifferentiated 
nasopharyngeal carcinoma.6
The occurrence of radioresistance is a 
multistage process involving many genes. 
Gene fractions that have functions in cell 
cycle control, apoptosis/antiapoptosis 
and DNA repair are presumed to have an 
important role in radiation-induced DNA 
damage. However, the mechanism of 
radioresistance at the molecular level is not 
fully understood.7,8 DNA damage caused by 
radiation is associated with regulation in the 
cell cycle.9
Cyclin D1 is the most type of cyclin 
that closely related to the genes involved in 
the cell cycle. Cyclin D1 is a core protein 
that bound to CDK4/CDK6 forming the D1-
CDK4/6 cyclin complex, which is involved 
in the phosphorylation of retinoblastoma 
proteins (pRb) in the G1 and S cell cycle 
phases and plays an important role in 
assisting cellular DNA repair.10
Radioresistance of tumor cells is also 
associated with angiogenesis process. Rapid 
tumor growth can lead to hypoxia so that 
tumor cells will initiate survival mechanism 
by activating vascular endothelial growth 
factor (VEGF), which causes increased 
vascular proliferation and angiogenesis. 
The newly formed blood vessels facilitate 
the provision of oxygen and nutrients 
to tumor cells. This condition can cause 
radioresistance on tumor cells. The VEGF is 
an angiogenic protein that plays a role in the 
growth of endothelial cells and tumor blood 
vessels.10,11 The aim of this study was to 
evaluate the association between expression 
of cyclin D1 and VEGF with radiotherapy 
response in undifferentiated nasopharyngeal 
carcinoma.
radioresisten dan pada 54,5% kelompok radiosensitif (p>0.05). Dapat disimpulkan, 
terdapat hubungan signifikan antara ekspresi siklin D1 dengan respons radioterapi pada 
karsinoma nasofaring tidak berdiferensiasi. Akan tetapi  tidak terdapat hubungan antara 
ekspresi VEGF dengan respons radioterapi.
 
Keywords: cyclin d1- nasopharyngeal carcinoma - radiotherapy – VEGF - response
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MATERIALS AND METHODS
Sample
The sample of this study was 
secondary data from medical records of 
patients diagnosed as undifferentiated 
nasopharyngeal carcinoma stage IV who only 
received a complete radiotherapy as they did 
not meet the requirements for chemotherapy, 
at the Department of Radiation Oncology, Dr 
Hasan Sadikin General Hospital, Bandung 
period 2012-2016. There were 44 samples 
eligible for inclusion criteria divided into 
radiosensitive and radioresistant groups 
based on radiotherapy response according 
to the agreement of the response evaluation 
criteria in solid tumors (RECIST). The 
RECIST criteria divide the radiotherapy 
response into a complete, partial, stable, 
and progressive response.12 Complete 
responses were incorporated into the 
radiosensitive group, while the partial, 
stable and progressive responses were 
incorporated into the radioresistant group. 
Both radiosensitive and radioresistant 
groups consisted of 22 samples for each 
group. Immunohistochemical examination 
of cyclin D1 and VEGF was performed on 
the paraffin block of patient nasopharyngeal 
taken from biopsy of the radiosensitive 
and radioresistant groups. Paraffin block 
preparations were available from medical 
records Department of Pathology, Dr. 
Hasan Sadikin General Hospital, Bandung, 
Indonesia.
Immunohistochemistry (IHC) examination
Cyclin D1 antibody (Clone SP4, 
Biocare, USA) and VEGF antibody 
(Clone EP117Y, Biocare, USA) was used 
as standard procedure of IHC staining. 
Positively stained tumor cells were counted 
visually using binocular photon micro-scope 
at 400x magnification, and scoring was 
made according to percentage and intensity 
of positively stained cells. Cyclin D1 
expressions were considered positive if the 
nuclear was stained and VEGF expressions 
were considered positive if the cell membrane 
and cytoplasm was stained.  The intensity of 
cyclin D1 and VEGF immunoexpressions 
was assessed on a scale of 0-3 (0, colorless; 
1+, weak colored; 2+, medium-colored; 3+, 
strongly colored) and the distribution of 
cyclin D1 and VEGF immunoexpressions 
was assessed on a scale of 0-4 (0, negative; 
+1, <20%; 2+, 20-50%; 3+, 50-80%; 
4+,> 80%). The immunoexperpression 
assessment of cyclin D1 and VEGF using 
Histoscore determined based on the number 
of multiplication intensities and distributions 
with a weak expression if total score is 0-4 
and strong expressions if total score 6-12.10,13 
The diagnosis was established by anatomic 
pathologist at the Department of Anatomic 
Pathology, Dr. Hasan Sadikin General 
Hospital, Bandung.
Statistic analysis
The data were presented as frequency or 
percentage and analyzed using Chi Square 
test with SPSS 22.0 software for Windows. 
Significant results were based on statistical 
calculations when obtained p value  ≤ 0.05.
RESULTS
TABLE 1 shows the characteristics of 
the study subjects consist of age, sex, stage 
based on radiotherapy response. Most cases 
were found in the 40-60 years age range of 
24 cases (55%). Males were observed more 
than females with 32 cases (73%). Most 
stages were IVB stage with 27 cases (61.4%) 
and were IV stage with metastasis to lymph 
nodes with 36 cases (82%).
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TABLE 2. Associationof imunnoexpression cyclin D1 and VEGF with radiotherapy 
response
Variable
Radiotherapy response [n(%)]
pSensitive Resistant
(n=22) (n=22)
Cyclin D1 
•	 Weak (0-4) 9 (40.9) 3 (13.6)
0.042**•	 Strong (6-12) 13 (59.1) 19 (86.4)
VEGF 
•	 Weak (0-4) 10 (45.5) 5 (22.7)
0.112•	 Strong (6-12) 12 (54.5) 17 (77.3)
A B
C D
TABLE 1. Characteristics of subjects based on radiotherapy response
Variable
Radiotherapy response  [n (%)]
pSensitive Resistant
(n=22) (n=22)
Age
•	 <40 years 6 (27.3) 7 (31.8)
0.987•	 40-60 years 11 (50.0) 13 (59.1)
•	 >60 years 5 (22.7) 2 (9.1)
Sex
•	 Man 14 (63.6) 18 (81.8)
0.176•	 Woman 8 (36.4) 4 (18.2)
Staging
•	 IVA
0.987
•	 T4N0M0 5 (22.7) 3 (13.6)
•	 T4N1-2M0 5 (22.7) 4 (18.2)
•	 IVB
•	 Any T N3 M0 12 (54.5) 15 (68.2)
•	 IVC
•	 Any T Any N M1 0 (0.0) 0 (0.0)
TABLE 2 shows the association of 
cyclin D1 and VEGF expression with 
radiotherapy response. Cyclin D1 expession 
statistically showed significant association 
(p=0.042), whereas VEGF expression 
showed nonsignificant association (p = 
0.112) with the radiotherapy response.
FIGURE 1. Cyclin D1 and VEGF expressions of nasopharyngeal carcinoma (A) 
Cyclin D1 strong expression, tumor cells were stained in the nuclear  
(B) Cyclin D1 weak expression (C) VEGF strong expression, tumor 
cells were stained in the cell membrane and cytoplasm (D) VEGF weak 
expression. (400X Magnification)
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DISCUSSION
In this study, most cases (24 cases) were 
found in the range 40-60 years old (55%) 
with males 3 times more than females. This is 
consistent with the study of Peterrson et al.,1 
stated that in high populations of NPC, the 
incidence increases after the age of 30 years 
and reaches peak incidence in the range 40-
60 years old, with male 2-3 times more than 
female. In this study, 36 cases (82%) of stage 
IV NPC have metastasized to lymph nodes. 
This is consistent with the study of Xuan 
et al.14 that found 70% of cases of stage IV 
NPC have metastasized to lymph nodes.
The cyclin D1 experpression of all 
samples in this study showed positive 
expression, 32 cases (72.7%) showed strong 
expression and 12 cases (27.3%) showed 
weak expression. The comparison of cyclin 
D1 expression in the radiosensitive group and 
the radioresitant group showed significant 
result (p=0.043). This suggests that there was 
a significant association between cyclin D1 
expression and radiotherapy response. This 
is likely due to DNA damage by radiation 
activating the AKT/Cyclin D1/CDK4 
pathway. This AKT pathway facilitates the 
repair of DNA in tumor cells to provide tumor 
cell survival and subsequently contributes to 
radioresistance.11,15
The results of this study are consistent 
with previous studies. The study of Fu 
et. al.10 showed significant differences 
between strong cyclin D1 expression in 
the sensitive radiotherapy response group 
and in the insensitive group (p<0.05). 
Patients with weak cyclin D1 expression 
are more sensitive to radiation. The strongly 
expressed cyclin D1 causes G1-S phase 
shortening in the cell cycle results in 
uncontrolled cell proliferation and promotes 
tumor cell growth. Radiation-induced DNA 
damage can also activates cyclin D1 to assist 
the process of DNA repair, thus increasing 
tumor cell survival and results in resistance 
to radiotherapy.10 Cyclin D1 depletion in 
HeLa cervical carcinoma cells and H2009 
lung cancer cells significantly increases the 
sensitivity of cancer cells to radiation. This 
suggests cyclin D1 to play a role in repairing 
damaged DNA.16 Cyclin D1 is an important 
key to cell cycle progression through 
G1 phase associated with poor radiation 
response. In other study, decreased cyclin 
D1 in esophageal cancer can slow down 
tumor cell growth and can reduce the DNA 
repair capacity of tumor cells. Inhibition of 
cyclin D1 can prevent DNA repair of tumor 
cells.17
In this study, all VEGF immunoxpression 
showed positive expression, 29 cases 
(65.9%) showed strong expression and 15 
cases (34.1%) showed weak expression. 
The results of this study show no significant 
association between VEGF expression with 
radiotherapy response (p=0.117). This may 
be caused by the hypoxic state that induces 
HIFα and results in radioresistance occurring 
through multiple pathways. These pathways 
are HIF1α/VEGF pathways, HIFα/CXCL12 
pathways, HIFα/ Transforming Growth 
Factor β (TGFβ) pathways and HIFα/TGFβ/
integrin pathways. HIFα / VEGF pathways 
and HIFα / CXCL12 pathways induce 
angiogenesis and vasculogenesis. The HIFα/
TGFβ pathway induces angiogenesis and 
maintains vascular homeostasis, whereas 
HIFα/TGFβ/integrin pathway may cause 
endothelial cell survival against radiation 
effects.18 In this study, another possible 
factor that induces angiogenesis, other 
than VEGF as mentioned above, is more 
dominant in causing the occurrence of 
radioresistance. Thus, this study found 
unsignifficant association between VEGF 
with radiotherapy response.
It was explained that in nasopharyngeal 
carcinoma, the oxygen factor alone is not 
sufficient to predict radiosensitivity, there 
are many other biological factors that 
involve in radiosensitivity.19 Moreover, 
the amount of angiogenic factors influence 
the pathway of radioresistance. Tumor 
cells with a few angiogenic factors will 
become radioresistence via hypoxic 
pathways, whereas tumor cells that have 
much of angiogenic factors will become 
radioresistance through intrinsic pathways 
and ischemic factors. These mechanisms 
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can cause undetectable VEGF expression in 
radioresistance.20
The factors mentioned above may 
induce the occurrence of nasopharyngeal 
carcinoma metastases into the lymph 
nodes.21 CXCL12 expression is increased 
in cases of nasopharyngeal carcinoma with 
lymph node metastasis compared to cases 
without metastasis to lymph nodes. CXCL12 
which forms the bond with CXCR4/CXCR7 
may affect migration, invasion and survival 
of nasopharyngeal carcinoma cells.22 TGFβ 
may serve as a protooncogen at an advanced 
stage by stimulating angiogenesis and 
inducing epithelial mesenchymal tumors 
(EMT) that contribute to tumor cell invasion 
and metastasis.23 Expression of integrin αv 
is significantly associated with lymph node 
metastasis in nasopharyngeal carcinoma. 
Integrin is a molecule that involves in the 
process of invasion, metastasis, angiogenesis 
and tumor cell survival.14 In this study, 82% 
of cases have metastasized to lymph nodes. 
This suggests that all factors mentioned 
above may be more dominant than VEGF 
in causing radioresistence, thus in this study 
there was no significant association between 
VEGF and radiotherapy response.
CONCLUSION
There is significant association 
between cyclin D1 expression with 
radiotherapy response in undifferentiated 
nasopharyngeal carcinoma. The stronger 
cyclin D1 expression, the higher likelihood 
of radioresistancy is observed. However, 
VEGF expression shows no significant 
association with radiotherapy response.
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